Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 54Lymphoma, Mantle-Cell 31Lymphoma, Large B-Cell, Diffuse 17Lymphoma, Non-Hodgkin 14Lymphoma 11Leukemia, B-Cell 7Lymphoma, Follicular 5Lymphoma, B-Cell, Marginal Zone 5Lymphoma, B-Cell 5Leukemia 5Waldenstrom Macroglobulinemia 4Multiple Myeloma 3Recurrence 2Pancreatic Neoplasms 2Lymphoproliferative Disorders 2Lymphatic Diseases 2Leukemia, Prolymphocytic 2Hematologic Neoplasms 2Cardiovascular Diseases 2Squamous Cell Carcinoma of Head and Neck 1Pyloric Stenosis, Hypertrophic 1Part1: Advanced B-cell Malignancies 1Ovarian Neoplasms 1Neuritis 1Neoplasms 1Neoplasm, Residual 1Leukemia, Hairy Cell 1Immunoproliferative Disorders 1Immune System Diseases 1Hodgkin Disease 1

Interventions

Oxaliplatin 2Leucovorin 2Fluorouracil 2dolutegravir 1acalabrutinib 1Yoga 1Tenofovir 1Rituximab 1Real-Time Polymerase Chain Reaction 1Pentoxifylline 1Massage 1Magnetic Resonance Spectroscopy 1Ketotifen 1Exercise 1Diffusion Tensor Imaging 1Bestrophins 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuritis × acalabrutinib × Clear all
NCT05065554 2025-12-05

ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
12 enrolled
Lymphoid

Waldenstrom Macroglobulinemia, Neuritis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡